{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:30:03Z","timestamp":1768483803964,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,4,21]],"date-time":"2014-04-21T00:00:00Z","timestamp":1398038400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00280-014-2446-4","type":"journal-article","created":{"date-parts":[[2014,4,20]],"date-time":"2014-04-20T06:28:07Z","timestamp":1397975287000},"page":"1129-1136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails"],"prefix":"10.1007","volume":"73","author":[{"given":"Weiheng","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangjuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangming","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jindi","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,21]]},"reference":[{"issue":"23","key":"2446_CR1","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","volume":"358","author":"PJ Hesketh","year":"2008","unstructured":"Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482\u20132494. doi: 10.1056\/NEJMra0706547","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"2446_CR2","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","volume":"21","author":"F Roila","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, Group EMGW (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232\u2013v243. doi: 10.1093\/annonc\/mdq194","journal-title":"Ann Oncol"},{"issue":"31","key":"2446_CR3","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical Oncology (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189\u20134198. doi: 10.1200\/JCO.2010.34.4614","journal-title":"J Clin Oncol"},{"issue":"3","key":"2446_CR4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1634\/theoncologist.4-3-191","volume":"4","author":"PJ Hesketh","year":"1999","unstructured":"Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4(3):191\u2013196","journal-title":"Oncologist"},{"issue":"9","key":"2446_CR5","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.1999.17.9.2971","volume":"17","author":"RJ Gralla","year":"1999","unstructured":"Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17(9):2971\u20132994","journal-title":"J Clin Oncol"},{"issue":"4","key":"2446_CR6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.1991.9.4.675","volume":"9","author":"F Roila","year":"1991","unstructured":"Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D et al (1991) Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9(4):675\u2013678","journal-title":"J Clin Oncol"},{"issue":"8765","key":"2446_CR7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0140-6736(91)90555-4","volume":"338","author":"DB Smith","year":"1991","unstructured":"Smith DB, Newlands ES, Rustin GJ, Begent RH, Howells N, McQuade B, Bagshawe KD (1991) Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 338(8765):487\u2013490","journal-title":"Lancet"},{"issue":"Suppl 1","key":"2446_CR8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000227642","volume":"53","author":"J Verweij","year":"1996","unstructured":"Verweij J, de Wit R, de Mulder PH (1996) Optimal control of acute cisplatin-induced emesis. Oncology 53(Suppl 1):56\u201364","journal-title":"Oncology"},{"issue":"2","key":"2446_CR9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1523-5394.1999.07205.x","volume":"7","author":"C Lindley","year":"1999","unstructured":"Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins S, Sawyer WT (1999) Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract 7(2):59\u201365","journal-title":"Cancer Pract"},{"issue":"5","key":"2446_CR10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497\u2013503. doi: 10.1007\/s00520-006-0173-z","journal-title":"Support Care Cancer"},{"issue":"16","key":"2446_CR11","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJM198110153051609","volume":"305","author":"J Laszlo","year":"1981","unstructured":"Laszlo J, Lucas VS Jr (1981) Emesis as a critical problem in chemotherapy. N Engl J Med 305(16):948\u2013949. doi: 10.1056\/NEJM198110153051609","journal-title":"N Engl J Med"},{"issue":"12","key":"2446_CR12","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1007\/s00520-012-1448-1","volume":"20","author":"P Fernandez-Ortega","year":"2012","unstructured":"Fernandez-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A, Suarez C, Zorrilla I, Gomez J, Zabaleta P, Nocea G, Llombart-Cussac A (2012) Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients\u2019 quality of life. Support Care Cancer 20(12):3141\u20133148. doi: 10.1007\/s00520-012-1448-1","journal-title":"Support Care Cancer"},{"issue":"3","key":"2446_CR13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/00003495-200060030-00002","volume":"60","author":"P Diemunsch","year":"2000","unstructured":"Diemunsch P, Grelot L (2000) Potential of substance P antagonists as antiemetics. Drugs 60(3):533\u2013546","journal-title":"Drugs"},{"issue":"12","key":"2446_CR14","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090\u20133098. doi: 10.1002\/cncr.11433","journal-title":"Cancer"},{"issue":"22","key":"2446_CR15","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2013the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112\u20134119. doi: 10.1200\/JCO.2003.01.095","journal-title":"J Clin Oncol"},{"issue":"22","key":"2446_CR16","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2003.10.128","volume":"21","author":"R Wit de","year":"2003","unstructured":"de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ (2003) Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21(22):4105\u20134111. doi: 10.1200\/JCO.2003.10.128","journal-title":"J Clin Oncol"},{"issue":"7","key":"2446_CR17","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/cncr.21343","volume":"104","author":"J Herrstedt","year":"2005","unstructured":"Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F, Aprepitant Moderately Emetogenic Chemotherapy Study Group (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104(7):1548\u20131555. doi: 10.1002\/cncr.21343","journal-title":"Cancer"},{"issue":"2","key":"2446_CR18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1124\/jpet.110.166181","volume":"335","author":"C Rojas","year":"2010","unstructured":"Rojas C, Li Y, Zhang J, Stathis M, Alt J, Thomas AG, Cantoreggi S, Sebastiani S, Pietra C, Slusher BS (2010) The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 335(2):362\u2013368. doi: 10.1124\/jpet.110.166181","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"2446_CR19","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00520-008-0545-7","volume":"17","author":"PJ Hesketh","year":"2009","unstructured":"Hesketh PJ, Younger J, Sanz-Altamira P, Hayden M, Bushey J, Trainor B, Krentzin M, Nowd P, Arnaoutakis K, Hesketh AM (2009) Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer 17(8):1065\u20131070. doi: 10.1007\/s00520-008-0545-7","journal-title":"Support Care Cancer"},{"issue":"1\u20132","key":"2446_CR20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000183735","volume":"32","author":"K Abbrederis","year":"2009","unstructured":"Abbrederis K, Lorenzen S, Rothling N, Ihbe-Heffinger A, Schuster T, Peschel C, Lordick F (2009) Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant. Onkologie 32(1\u20132):30\u201334. doi: 10.1159\/000183735","journal-title":"Onkologie"},{"issue":"12","key":"2446_CR21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1159\/000096689","volume":"29","author":"K Oechsle","year":"2006","unstructured":"Oechsle K, M\u00fcller MR, Hartmann JT, Kanz L, Bokemeyer C (2006) Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone. Onkologie 29(12):557\u2013561","journal-title":"Onkologie"},{"issue":"10","key":"2446_CR22","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","volume":"100","author":"SM Grunberg","year":"2004","unstructured":"Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100(10):2261\u20132268. doi: 10.1002\/cncr.20230","journal-title":"Cancer"},{"key":"2446_CR23","doi-asserted-by":"crossref","unstructured":"Roila F (2000) Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research. Support Care Cancer 8(3):229-232","DOI":"10.1007\/s005200050290"},{"issue":"11","key":"2446_CR24","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1002\/cncr.11408","volume":"97","author":"JT Hickok","year":"2003","unstructured":"Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 97(11):2880\u20132886. doi: 10.1002\/cncr.11408","journal-title":"Cancer"},{"issue":"10","key":"2446_CR25","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00520-004-0662-x","volume":"12","author":"A Glaus","year":"2004","unstructured":"Glaus A, Knipping C, Morant R, Bohme C, Lebert B, Beldermann F, Glawogger B, Ortega PF, Husler A, Deuson R (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12(10):708\u2013715. doi: 10.1007\/s00520-004-0662-x","journal-title":"Support Care Cancer"},{"issue":"3","key":"2446_CR26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1056\/NEJM199901213400304","volume":"340","author":"RM Navari","year":"1999","unstructured":"Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 340(3):190\u2013195. doi: 10.1056\/NEJM199901213400304","journal-title":"N Engl J Med"},{"issue":"6","key":"2446_CR27","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1200\/JCO.2001.19.6.1759","volume":"19","author":"D Campos","year":"2001","unstructured":"Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19(6):1759\u20131767","journal-title":"J Clin Oncol"},{"issue":"3","key":"2446_CR28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-008-9957-9","volume":"113","author":"W Yeo","year":"2009","unstructured":"Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B (2009) A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 113(3):529\u2013535. doi: 10.1007\/s10549-008-9957-9","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"2446_CR29","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011\u20131015. doi: 10.1038\/sj.bjc.6603048","journal-title":"Br J Cancer"},{"issue":"8","key":"2446_CR30","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s00520-011-1280-z","volume":"20","author":"Y Jin","year":"2012","unstructured":"Jin Y, Wu X, Guan Y, Gu D, Shen Y, Xu Z, Wei X, Chen J (2012) Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis. Support Care Cancer 20(8):1815\u20131822. doi: 10.1007\/s00520-011-1280-z","journal-title":"Support Care Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2446-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2446-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2446-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T02:53:54Z","timestamp":1597719234000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2446-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,21]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["2446"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2446-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,21]]}}}